Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Coverage of the 14th European AIDS Conference

HIVandHepatitis.com coverage of the 14th European AIDS Conference, sponsored by the European AIDS Clinical Society (EACS), October 16-19, 2013, in Brussels.

Conference highlights include antiretroviral therapy strategies and new HIV drugs, new treatment for hepatitis C, biomedical HIV prevention, HIV cure research, and the epidemic in Eastern Europe.

Full listing by topic

10/20/13

alt

 

 

EACS 2013: Dual Therapy with Kaletra + Lamivudine Works Well Regardless of Viral Load

A dual combination of lopinavir/ritonavir (Kaletra or Aluvia) plus lamivudine (3TC or Epivir) as first-line therapy produced good virological suppression regardless of baseline viral load and was well-tolerated in the multinational GARDEL study, according to a late-breaking report at the 14thEuropean AIDS Conference this week in Brussels.

alt

Read more:

EACS 2013: New European Treatment Guidelines Strike Balance Between Individual Choice and Public Health

A new edition of the European AIDS Clinical Society (EACS) guidelines for the treatment of HIV, HIV/hepatitis C coinfection, and HIV with other comorbidities were published in advance of the 14th European AIDS Conference currently taking place in Brussels and were presented and discussed at a special session and press conference Friday.

alt

Read more:

EACS 2013: GSK1265744 Rapidly Suppresses HIV, Appears Safe At Selected Dose

The experimental HIV integrase inhibitor GSK1265744 demonstrated rapid and potent antiviral activity and good tolerability for treatment-naive patients in the LATTE study, according to a report at the 14th European AIDS Conference this week in Brussels.

alt

Read more:

EACS 2013: Experts Debate Whether HIV Cure Is "Hype or Hope"

Is a functional cure for HIV feasible within the foreseeable future, or is it a hopeless quest robbing resources from more practical approaches to improve the lives of people living with HIV? This question was the crux of a mock trial held Wednesday on the opening day of the 14th European AIDS Conference (EACS 2013) in Brussels.

alt

Read more:

European AIDS Conference Features Latest HIV & Hepatitis C Data, New Guidelines

The European AIDS Conference, the biennial meeting of the European AIDS Clinical Society (EACS), opened Wednesday in Brussels, the site of the organization's first meeting 25 years ago. The conference included the latest news on antiretroviral therapy (ART) for HIV, hepatitis C treatment for HIV/HCV coinfected people, and biomedical HIV prevention, as well as the launch of updated European treatment guidelines.

alt

Read more:

EACS 2013: Cenicriviroc Shows Good Activity Against HIV, New Formulation May Reduce Dropouts

The dual CCR5/CCR2 inhibitor cenicriviroc demonstrated good antiviral activity and tolerability in a Phase 2 clinical trial, according to a report at the 14th European AIDS Conference (EACS 2013) this week in Brussels. The study had many dropouts, likely due to its complex dosing regimen, but a more user-friendly cenicriviroc formulation has since been developed.

alt

Read more: